Skip to content

Avalo Therapeutics AVTX Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-88.8%-16.3pp-72.4%+105pp-177.4%
Liquidity
Current ratio7.7×-0.5×8.1×-6.1×14.3×+1.8×12.4×-10.2×22.6×+2.7×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$3.40-45.2%$6.20-5.3%$6.54-32.3%$9.66-17.2%$11.66-34.3%
Valuation
Market capitalization$954.59M+1,783%$329.31M+97.0%$167.17M+212%$53.6M-37.3%$85.48M+10.0%
Price / book13.8×+13.4×+2.1×1.8×+1.3×0.5×-0.2×0.7×+0.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Avalo Therapeutics's profit margins?
Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
Where do Avalo Therapeutics's ratios come from?
Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.